- Home
- EXEL vs SIRI Comparison
EXEL vs SIRI Comparison
Compare EXEL & SIRI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EXEL
- SIRI
- Stock Information
- Founded
- EXEL 1994
- SIRI 2013
- Country
- EXEL United States
- SIRI United States
- Employees
- EXEL N/A
- SIRI N/A
- Industry
- EXEL Biotechnology: Biological Products (No Diagnostic Substances)
- SIRI Broadcasting
- Sector
- EXEL Health Care
- SIRI Consumer Discretionary
- Exchange
- EXEL Nasdaq
- SIRI Nasdaq
- Market Cap
- EXEL 9.8B
- SIRI N/A
- IPO Year
- EXEL 2000
- SIRI 1994
- Fundamental
- Price
- EXEL $36.73
- SIRI $21.44
- Analyst Decision
- EXEL Buy
- SIRI Hold
- Analyst Count
- EXEL 18
- SIRI 15
- Target Price
- EXEL $37.59
- SIRI $26.90
- AVG Volume (30 Days)
- EXEL 2.3M
- SIRI 4.1M
- Earning Date
- EXEL 05-13-2025
- SIRI 05-01-2025
- Dividend Yield
- EXEL N/A
- SIRI 5.11%
- EPS Growth
- EXEL 170.77
- SIRI N/A
- EPS
- EXEL 1.76
- SIRI N/A
- Revenue
- EXEL $2,168,701,000.00
- SIRI $8,605,000,000.00
- Revenue This Year
- EXEL $5.78
- SIRI N/A
- Revenue Next Year
- EXEL $10.94
- SIRI $0.31
- P/E Ratio
- EXEL $20.74
- SIRI N/A
- Revenue Growth
- EXEL 18.50
- SIRI N/A
- 52 Week Low
- EXEL $20.14
- SIRI $18.69
- 52 Week High
- EXEL $40.26
- SIRI $41.60
- Technical
- Relative Strength Index (RSI)
- EXEL 49.28
- SIRI 51.37
- Support Level
- EXEL $34.90
- SIRI $20.89
- Resistance Level
- EXEL $40.26
- SIRI $21.85
- Average True Range (ATR)
- EXEL 1.18
- SIRI 0.81
- MACD
- EXEL -0.13
- SIRI 0.17
- Stochastic Oscillator
- EXEL 40.67
- SIRI 76.92
About EXEL Exelixis Inc.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.